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Abstract—Advances in pediatric cancer treatment have led to a ten year survival rate greater than 75%. Platinum-
based chemotherapies (e.g. cisplatin) induce peripheral sensory neuropathy in adult and pediatric cancer
patients. The period from birth through to adulthood represents a period of maturation within nociceptive sys-
tems. Here we investigated how cisplatin impacts upon postnatal maturation of nociceptive systems. Neonatal
Wistar rats (Postnatal day (P) 7) were injected (i.p.) daily with either vehicle (PBS) or cisplatin (1mg/kg) for ﬁve
consecutive days. Neither group developed mechanical or thermal hypersensitivity immediately during or after
treatment. At P22 the cisplatin group developed mechanical (P< 0.05) and thermal (P< 0.0001) hypersensitivity
versus vehicle group. Total DRG or dorsal horn neuronal number did not diﬀer at P45, however there was an
increase in intraepidermal nerve ﬁber density in cisplatin-treated animals at this age. The percentage of IB4+ve,
CGRP+ve and NF200+ve DRG neurons was not diﬀerent between groups at P45. There was an increase in TrkA
+ve DRG neurons in the cisplatin group at P45, in addition to increased TrkA, NF200 and vGLUT2 immunoreac-
tivity in the lumbar dorsal horn versus controls. These data highlight the impact pediatric cancer chemotherapy
has upon the maturation of pain pathways and later life pain experience.
This article is part of a Special Issue entitled: SI: Pain Circuits. Crown Copyright  2017 Published by Elsevier Ltd on behalf of
IBRO. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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44INTRODUCTION
Platinum-based chemotherapies (e.g. oxaliplatin,
cisplatin) are front line cancer treatments (van As et al.,
2012). However, these cytotoxic drugs not only target
cancerous cells but also other non-cancerous cell types
and thus produce considerable side-eﬀects. Up to 95%
of adult patients suﬀer from sensory complications
(e.g. pain, numbness) during or following chemotherapy,
which typically aﬀect the extremities (hands and feet)
(Paice, 2011; Giles et al., 2007). Consequently
chemotherapy-induced sensory neuropathies (CIPN)
can impede success of treatment and in some cases lead
to treatment being terminated (Park et al., 2013). Many
adult-patients suﬀer CIPN after initial cisplatin exposure
(McWhinney et al., 2009), which can persist for many
months following cessation of treatment (Seretny et al.,
2014). Cisplatin-induced CIPN has been investigated45
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1extensively in rodent models (Joseph and Levine, 2009;
Uhelski et al., 2015) with translatable hallmarks of sen-
sory neuropathy presented such as sensory neuron
degeneration (intraepidermal sensory nerve ﬁber (IENF)
innervation loss and axonal degeneration) (Ta et al.,
2006; Mao-Ying et al., 2014) and sensory neuron hyper-
excitability (Joseph and Levine, 2009; Uhelski et al.,
2015).
Despite the signiﬁcant implications for adult cancer
survivors, understanding the impact of chemotherapy-
induced sensory neurotoxicity upon childhood cancer
survivors has not been extensively investigated. Against
a background of increased cancer patient survival rates
in the general population, improvements in treating
pediatric cancer has resulted in survival rates of 75%
surviving longer than 5–10 years (Smith et al., 2010;
Ward et al., 2014). Pediatric cancer treatments are simi-
larly invasive to that in adults, with highly cytotoxic agents
administered and surgical interventions often required.
Evidence exists to show that chemotherapy treatment
early in life leads to a signiﬁcant decline in quality of life
in adult childhood cancer survivors. Typically many
patients complain of fatigue, anxiety and depression
(Clanton et al., 2011; Kunin-Batson et al., 2016) as well.
/licenses/by/4.0/).
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4 December 2017as impairment of the auditory system that signiﬁcantly
eﬀects social interactions and cognitive development
(Grewal et al., 2010). However, exposure to chemother-
apy at a young age leads to pain (Lu et al., 2011), espe-
cially in the extremities (hands, arms) Lu et al., 2011;
Gilchrist et al., 2014 and alterations in sensory function
(Ness et al., 2013). This pain manifests itself in adulthood
many years after diagnosis and discontinuation of treat-
ment (Ness et al., 2013; Khan et al., 2014; Phillips
et al., 2015). Cisplatin is a commonly utilized chemother-
apeutic agent used in pediatric oncology, for example in
treating hepatoblastoma (Zsiros et al., 2010; Zsiros
et al., 2013) and studies investigating neuropathy in sur-
vivors demonstrate that cisplatin treatment early in life
leads to the develop of pain in adulthood in these patients
(Gilchrist and Tanner, 2013; Gilchrist et al., 2014). How-
ever, there has currently been no investigation into the
mechanistic avenues by which cisplatin induces pain in
childhood cancer survivors.
Nociceptive pathways are not fully developed at birth
and maturation of the sensory nervous system during
early life is greatly manipulated by disease and injury
(Fitzgerald, 2005). During infancy the peripheral nervous
system is still developing. The central terminals of primary
aﬀerent sensory neurons are still to be ‘hard wired’ and
physiological properties of dorsal horn networks that are
activated by these aﬀerents are also immature. Nerve
injury early in life has been shown to result in a
pronounced hyperalgesia that emerges in adulthood
(Vega-Avelaira et al., 2012; McKelvey et al., 2015). This
study was designed to determine whether cisplatin treat-
ment early in life leads to an alteration in pain perception
in adulthood. In Sprague–Dawley rats we report alter-
ations in behavioral pain thresholds following cessation142
Pain Behaviour
P0 P7
Treatment
5 daily I.P. injections 
(->) Vehicle or 
(1mg/kg) Cisplatin
A P13of treatment that persisted into adult-
hood, which is accompanied by
changes in the classiﬁcation of dorsal
root ganglia (DRG) sensory neurons
and alterations in sensory nerve ﬁber
termination in the skin and spinal dorsal
horn (DH).B C
Fig. 1. Cisplatin treatment results in a delayed mechanical and thermal hypersensitivity. [A] P7
rats were treated with either i.p. injections of vehicle or cisplatin (1 mg/kg) for 5 consecutive days.
[B] Experimental groups of animals did not display any alterations in mechanical withdrawal
threshold between P6 and P20. However, from P22 to the end of the experiment the cisplatin-
treated animals displayed a reduction in withdrawal threshold to mechanical stimulation when
compared to vehicle injection (*P< 0.05, ***P< 0.001 Two ANOVA with post Bonferroni test;
vehicle = 7, cisplatin n= 5). [C] In response to heat, animals from both experimental groups
demonstrated similar withdrawal latencies. At P22 cisplatin-treated animals displayed a reduction
in withdrawal latency to heat stimulation (**P< 0.01, ***P< 0.001 Two ANOVA with post
Bonferroni test; vehicle = 7, cisplatin n= 5).EXPERIMENTAL PROCEDURES
Animals
Time mated pregnant Wistar rat dams
were bought from Charles River UK,
They were received into The
University of Nottingham Biological
Services Unit at E17 and allowed to
habituate prior to partuition.
Experiments were conducted under
UK Home Oﬃce regulations and in
concordance with the Animal
(Scientiﬁc Procedures) Act (1986) and
adhered to the ARRIVE Guidelines.
Ethical approval was granted by the
University of Nottingham Animal
Welfare and Ethical Review Board.
Animals were housed in light/dark
(12:12 h) cycled rooms. Pups werePlease cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mhoused with their mother and littermates until P21 when
they were weaned. Post-weaning rats were housed in
single-sex cages of six animals with access to food and
water ab libitum. Experimenters were blinded to all
treatment groups at all stages.Nociceptive behavioral experiments
Pups of both genders were randomly assigned to two
groups, vehicle (n= 22) and cisplatin (n= 19) at birth
(Postnatal (P) 0). Animals were treated with
experimental agents from P7. The vehicle group were
administered PBS (phosphate-buﬀered saline) and the
treatment group administered cisplatin
(1mg/kg dissolved in PBS) intraperitoneal (i.p.)
injections once a day for ﬁve consecutive days (Fig. 1A)
in two cohorts. In reference to human cisplatin
administration, a single cycle of cisplatin treatment
(typically between 60 and 100 mg/m2, every 3 weeks
(Zsiros et al., 2010), with for example hepatoblastoma
patients 19.1 months old (median age) receive 70 mg/m2-
/cycle patients (Zsiros et al., 2013). The dose of cisplatin
used in this study is comparable to adult rodent studies
which demonstrate sensory neuropathy (Park et al.,
2013; Uhelski et al., 2015). One cohort was terminated
at P16 (Immature) (vehicle (n= 8) and cisplatin
(n= 11) the remainder remained in the study until P45
(adult). Prior to behavioral testing animals were habitu-
ated to handling and the room in which testing occurred.
Mechanical withdrawal threshold and withdrawal latency
to heat were measured as previously described
(Vencappa et al., 2015). Mechanical threshold was mea-
sured using von Frey ﬁlaments (Linton), which were
applied to the dorsal surface of the left and right hind
paw of pups (<P21) or the plantar surface in older ani-aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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4 December 2017mals (>P21). Each hair (expressed in grams) was
applied sequentially, ﬁve times each to determine
mechanical force withdrawal thresholds which was deter-
mined as the ﬁrst hair to elicit a withdrawal response in
40% of applications. Latency (seconds) to withdraw from
a thermal stimulus was achieved using the plantar test
(Hargreaves Apparatus, Ugo Basile). Thermal stimuli
were applied to both feet three times, with a rest period
between stimulations to avoid sensitization and the mean
latency to the three presentations calculated.
Immunohistochemistry
Animals were terminally anesthetized with sodium
pentobarbital (60 mg/ml; i.p.). The heart of each animal
was exposed and blood collected from the left ventricle
via cardiac puncture into heparinized tubes and stored
at 4 C. Animals were then perfused transcardially via
this cannula with ice-cold PBS (>100 ml) followed by
4% paraformaldehyde (PFA; >200 ml). Tissue (spinal
cord, L3-5 dorsal root ganglia (DRG), plantar hindpaw
skin-full plantar width skin biopsies were extracted from
mid-point of the heel to the proximal border of the
footpad (excluding footpads Thakur et al., 2012) was
collected and submerged in 4% PFA and left overnight
at 4 C. Tissues were then transferred to a 30% sucrose
(in Phosphate buﬀer saline (PBS)) solution, kept at 4 C
overnight. Samples were then frozen in optimum cutting
temperature (OCT) solution and stored at 80 C until
needed. Sections were cut using a cryostat and mounted
on a Superfrost Plus slides (VWR International) and
stored at 80 C. Dorsal root ganglia were cut at 6 mm,
plantar skin 20-mm thickness and spinal cord 40 mm.
Slides were placed in a humidiﬁed chamber and
washed with PBS solution (3 times for 5 min each) and
then with PBS 0.2% Triton x-100. Slides were incubated
in blocking solution (PBS 0.2% Triton x-100 5% Bovine
Serum Albumin (BSA) 10% Fetal Bovine Serum (FBS))
for 30 min at room temperature. Primary antibodies
were made up at required concentration in blocking
solution. Antibodies, concentrations, sources are: mouse
anti-NeuN (Millipore) (1 in100), Rabbit anti-protein gene
product 9.5 (PGP9.5) (Millipore, 1 in200), Rabbit anti-
calcitonin gene related peptide (CGRP) (Sigma, 1in
5000), mouse anti-Neuroﬁlament 200 (NF200) (Sigma, 1
in 1000), goat anti-tropomyosin receptor kinase A (TrkA)
(R&D Systems, 1 in 100), rabbit anti-cleaved caspase 3
(Cell Signalling, 1 in 500). These were incubated
overnight at 4 C. Slides were then washed a further 3
times (5 min) in PBS. In some cases biotinylated
antibodies were used (biotinylated donkey anti rabbit
and biotinylated donkey anti goat, Jackson, 1 in 500).
These were made up in PBS 0.2% Triton x-100 was
pipetted to slides and left at room temperature for 2 h.
These were washed 3 times (5 min) in. Slides were then
incubated in Alexaﬂuor antibody (Invitrogen, 1 in 1000)
diluted appropriately in PBS 0.2% triton x-100 and were
left in a dark environment at room temperature for 2 h.
Alexaﬂuors used were anti-mouse 488, streptavidin 555,
streptavidin 405, and anti-rabbit 555. These were
washed 3 times (5 min) in PBS. Slides were
coverslipped (22  50 mm) using Fluorsave (Millipore).Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the MFluoroshield with DAPI (Millipore) was used for the
plantar skin sections. Coverslips were sealed and stored
at 4 C in the dark. Slides were imaged using a Leica
SPE confocal microscope and Leica Application Suite
Software (TVBL imaging facility). Each DRG section
was imaged in its entirety and for the plantar skin slides
4–6 random images were taken per section to provide a
representation. The x10 objective was used to image
the DRGs and plantar skin sections for quantitative
analysis and the x63 objective was used to generate
high magniﬁcation images.
Spinal cords were cut at 40 mm using a microtome and
left in sucrose azide (0.04% %) overnight. Sucrose azide
was removed by washing in PBS (3 for 5 min). Slides
were incubated with 3% blocking solution (0.1 M PBS,
3% goat or donkey serum, 0.3% triton X-100) for one
hour at room temperature. Primary antibodies, sources,
concentrations and incubation times are: mouse anti
NeuN (Millipore, 1 in 500), rabbit anti-GFAP (AbCam, 1
in 500, Goat anti-TrkA (R&D Systems) (1 in 100),
overnight. (Donkey anti-goat biotin (1 in 500) 2 h),
Mouse anti-NF200 (Sigma) (1 in 750) 24 h, Rabbit anti-
VGLUT2 (Synaptic Systems) (1 in 750) 24 h. The slides
were then washed in PBS 5 for 10 min. Life
technologies alexaﬂuors used were; Streptavidin 405
(1 in 1000), anti-mouse 488 (1 in 500), anti-rabbit 555
(1 in 500). Samples were incubated for 2 h at room
temperature in the dark, before washing in PBS 5 for
10 min. Sections were mounted on gelatinized slides
and allowed to dry overnight in the dark. Slides were
coverslipped (22  50 mm) using Fluromount (Sigma),
sealed and stored in the dark at 4 C. Slides were
imaged using a Leica SPE confocal microscope and
Leica Application Suite Software (TVBL imaging facility),
the dorsal horn of the spinal cord was imaged using the
10 objective.
Analysis
Analysis was completed using Microsoft Excel and
GraphPad Prism v 6.0 software. All data are presented
as mean ± SEM. The area per ﬁeld of view is 1.10 mm
 1.10 mm at 10 magniﬁcation. Neuronal number and
section area (mm2) were quantiﬁed automatically using
Image J software region of Interest (ROI) manager tool
(http://imagej.net/Welcome). IB4+, CGRP+, TrkA+ and
NF200+ neurons were calculated as a percentage of
the total DRG number (NeuN+/PGP9.5+stained). Total
DRG neuronal number was determined from using
PGP9.5 and NeuN co-staining and quantiﬁed per ROI
(whole DRG section). A minimum of 10 sections per
animal used and mean total sensory neuron count per
DRG was determined. It was determined that the total
neuronal number for PGP9.5 and NeuN was similar
between treatment groups (Fig. 5). IENF density were
quantiﬁed, using image J software, as ﬁbers entering
the epidermis (visualized with DAPI/dotted white line).
Numbers were normalized for epidermal length (mm)
and to the mean of vehicle animals. Five random
images were acquired per plantar skin sample per
animal with a minimum of 10 sections per animal used.
From these the average IENF density score wasaturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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4 December 2017calculated per animal. A minimum total of 7400 DRG
sensory neurons and 2100 IENF were analyzed over
the complete study. All DRG and IENF analysis
previously described (Hulse et al., 2015). Unpaired T test
was performed on the percentage DRG number and total
IENF density from plantar skin. Two-way ANOVA with
post hoc Bonferroni test was performed for DRG sensory
neuronal soma area analysis. Images of the spinal cords
were acquired and analyzed using the region of interest/-
plot proﬁle plugin in Image J. A total of 4 random regions
of interest were calculated and calibrated to depth of sec-
tion. Area under the curve (AUC) analysis and an
unpaired T Test were performed to determine dorsal horn
innervation. Nociceptive behavioral testing was analyzed
using a two-way ANOVA with post hoc Bonferroni test.
In the spinal cord stains: CGRP, IB4, TrkA, NF200
and vGLUT2 staining was analyzed by plotting four lines
of interest through each image in ImageJ to measure
gray value (AU) intensity using the plot proﬁle tool. EachFig. 2. Cisplatin treatment leads to sensory neurodegeneration. IENF meas
treated with either vehicle or cisplatin. [A&B] There was a reduction in CG
(IENF/mm, **P< 0.01 Unpaired T test; vehicle = 4, cisplatin n= 4; scale ba
treated animals when compared to vehicle (IENF/mm, *P< 0.05 Unpaired
Sensory DRG neurons were collected from both experimental groups; vehicle
DRG sensory neurons (NeuN+ve) in the cisplatin-treated animals versus v
scale bar = 20 mm).
Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mstraight plot line (ﬁxed width) extended ventrally 600 mm,
from the outer dorsal surface of sections/outer region of
lamina I, to lamina V of the dorsal horn. The origin of
each line was equally spaced following the outer curve
of the dorsal horn using a similar method as previously
described (Lorenzo et al., 2008). Results for each group
were averaged to give a single intensity proﬁle for cis-
platin and vehicle groups. The area under the curve
(AUC) was taken for the averaged intensity proﬁle to cre-
ate a ﬁgure for the entire dorsal horn. Results were tested
for parametric normality with D’Agostino and Pearson
omnibus normality test. Cisplatin and vehicle cell counts
were compared and analyzed for statistical signiﬁcance
using an unpaired T-test with Kolmogorov–Smirnov post
hoc test. In the spinal cord NeuN and GFAP cell counts
were taken from ﬁve 100 lm  100 lm regions of interest
(ROI) for lamina I, II and V of the dorsal horn, using the
ROI manager plugin on ImageJ. Results for each group,
were averaged to give a single cell count for each lamina,urements were taken from the hindpaw plantar skin from P16-20 rats
RP+ve IENF in the plantar skin of cisplatin animals versus vehicle
r = 100 mm). [C&D] PGP9.5+ve IENF was also reduced in cisplatin-
T test; vehicle = 4, cisplatin n= 4; scale bar = 100 mm). [E&F] L4
and cisplatin at P16-20. Cleaved caspase 3 (CC3) was increased in
ehicle rats (*P< 0.05 Unpaired T test; vehicle = 4, cisplatin n= 4;
aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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4 December 2017and then for the entire dorsal horn section to identify total
neuron or astrocyte number per dorsal horn of spinal cord
and of the designated laminae. Results were tested for
parametric normality with D’Agostino and Pearson
omnibus normality test. Cisplatin and vehicle cell counts
were compared and analyzed for statistical signiﬁcance
using an unpaired T-test with a Mann–Whitney test.
P values are represented as *P< 0.05, **P< 0.01 and
***P< 0.001. NS dictates not signiﬁcant.324
325
326
327
328
329
330RESULTS
Early-life cisplatin exposure leads to a delayed onset
of mechanical and thermal hypersensitivity
To assess whether cisplatin treatment results in sensory
abnormalities when administered in early-life dailyFig. 3. Cessation of cisplatin treatment induces neuroregeneration in adults
taken from hindpaws of both experimental groups; vehicle and cisplatin at
CGRP+ve IENF versus the vehicle groups (IENF/mm, **P< 0.01 Unpaired
was also increased in the plantar skin of cisplatin-treated animals when comp
vehicle = 5, cisplatin n= 5) (scale bar = 100 mm).
Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mintraperitoneal injections of either vehicle (PBS) or
Cisplatin (1mg/kg) starting on day P7, were performed
for 5 consecutive days. Cisplatin-treated animals
developed a persistent but delayed (onset P22)
mechanical hypersensitivity compared to vehicle-treated
rats, (Fig. 1B; *P< 0.05, ***P< 0.001 Two-way ANOVA
with post Bonferroni test) and this diﬀerence between
the two groups was maintained until the end of the
experiment (P42; Vehicle = 18.58 ± 1.09 g vs Cisplatin
= 9.03 ± 0.42 g). Heat hypersensitivity also developed
in the cisplatin group, with persistently shorter
withdrawal latencies evident from P22 to the end of the
study (P42; Vehicle = 9.82 ± 0.58 s vs Cisplatin = 5.3
4 ± 0.51 s) when compared to the vehicle treatment
group (Fig. 1C; **P< 0.01, ***P< 0.001 Two-way
ANOVA with post Bonferroni test).. CGRP+ve and PGP+ve IENF were measured in the plantar skin
P45. [A&B] In the cisplatin-treated animals there was an increase in
T test; vehicle = 5, cisplatin n= 5). [C&D] Similarly, PGP+ve IENF
ared to vehicle-treated animals (IENF/mm, *P< 0.05 Unpaired T test;
aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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4 December 2017Cisplatin treatment leads degeneration of the
peripheral nervous system
Cisplatin is a widely used cancer chemotherapeutic,
which in adults induces sensory neurodegeneration (Ta
et al., 2006; Mao-Ying et al., 2014). Intraepidermal nerve
ﬁber (IENF) density in the plantar skin and dorsal root
ganglia sensory neuron number were measured in vehicle
and cisplatin-treated animals a week (P16) post termina-
tion of treatment. Cisplatin exposure led to a reduction in
the number of CGRP positive (Fig. 2A, B; **P< 0.01
Unpaired T test; Vehicle = 10.98 ± 0.39 IENF/mm vs C
isplatin = 4.93 ± 1.44 IENF/mm) and PGP9.5 positive
(Fig. 2C&D; P< 0.05 Unpaired T test; Vehicle = 7.98
± 0.62 IENF/mm vs Cisplatin = 6.08 ± 0.32 IENF/mm)
IENFs in the plantar skin versus vehicle controls. At this
timepoint there were signiﬁcantly more L4 DRG neurons
positive for cleaved caspase 3 (CC3) in the cisplatin group
when compared to vehicle animals (Fig. 2E&F; **P< 0.01
Unpaired T test; Vehicle = 15.82 ± 3.43% vs Cisplatin
= 29.89 ± 1.49%). When pups were allowed to mature
to P45 following treatment with cisplatin between P7-11Fig. 4. Cisplatin does not alter sensory neuronal delineation. Sensory DRG n
diameter DRG sensory neuron populations in both vehicle and cisplatin-treate
diﬀerences between experimental groups in the percentage of [D] CGRP a
addition, DRG sensory neurons were labeled for the myelinated sensory neu
TrkA (peptidergic) in vehicle and cisplatin-treated P16 animals. These were
groups in the percentage of the [I] NF200 or [J] IB4 sensory DRG neuronal
Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mwe observed a signiﬁcant increase in the number of
CGRP (Fig. 3A, B, **P< 0.01 Un-paired T-test; Vehicle
= 7.76 ± 0.62 IENF/mm vs Cisplatin = 11.88 ± 0.90
IENF/mm) positive and PGP9.5 (Fig. 3C, D, *P< 0.05
Un-paired T-test; Vehicle = 7.25 ± 0.43 IENF/mm vs Cis
platin = 9.69 ± 0.36 IENF/mm)-positive IENF in plantar
hindpaw skin compared to controls.Cisplatin has no eﬀect on DRG cell populations
immediately following treatment
L4 DRG neurons extracted from vehicle and cisplatin-
treated animals aged P16 were stained for pan-neuronal
markers (Fig. 4) NeuN and PGP9.5. Sensory neurons
are often categorized on the basis of their expression of
neuropeptides (e.g. CGRP), lack of neuropeptides (IB4)
or markers of myelination (NF200). Sensory DRG
neurons were labeled with (Fig. 4A) CGRP and
(Fig. 4B) IB4, in addition to pan-neuronal marker
(Fig. 4C) NeuN. The percentage of speciﬁc sensory
neuronal subsets for (Fig. 4D) CGRP (Vehicle = 53.1
± 1.47 vs Cisplatin = 59.72 ± 2.09) and (Fig. 4E) IB4 (eurons were stained for [A] CGRP and [B] IB4 to represent the small
d P16 animals. These were co-localized with [C] NeuN. There were no
nd [E] IB4 (non-peptidergic) sensory DRG neuronal subclasses. In
ronal marker [F] NF200 and the small diameter neuronal marker [G]
co-localized with [H] PGP9.5. There were no diﬀerences between
subclasses (vehicle = 4, cisplatin n= 4; scale bar = 50 mm).
aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
G. J. Hathway et al. / Neuroscience xxx (2017) xxx–xxx 7
NSC 18147 No. of Pages 16
4 December 2017Vehicle = 49.53 ± 2.53% vs Cisplatin = 56.86 ± 2.63)
was unchanged between experimental groups. Sensory
DRG neurons extracted from age-matched vehicle and
cisplatin-treated animals aged P16 were labeled with
(Fig. 4F) NF200 and (Fig. 4G) TrkA, in conjunction with
a pan neuronal marker, (Fig. 4H) PGP9.5. The
percentage of total sensory neurons labeled with either
(Fig. 4I) NF200 (Vehicle = 51.58 ± 1.85% vs Cisplatin
= 55.91 ± 1.39) or (Fig. 4J) TrkA (Vehicle = 71.03 ± 2
.87% vs Cisplatin = 74.53 ± 1.73) were unchanged
between vehicle and cisplatin-treated groups at P16.403
404
405
406
407
408
409
410
411
412
413Cisplatin leads to long-term re-organization of the
peripheral nervous system
We next assessed whether there were any delayed
eﬀects of neonatal cisplatin treatment upon DRG
composition in rats at P45. We found that there were no
signiﬁcant diﬀerences in the total number of DRG
sensory neurons in either experimental group at P45
(Total DRG sensory neuron number Fig. 5A, B; NeuN;
NS Unpaired T test; (Vehicle = 64.05 ± 5.19 vs CisplaFig. 5. The eﬀect of cisplatin treatment on DRG sensory neurons. DRG sens
cisplatin treated) at the timepoint P45. DRG neurons were stained for NeuN
sensory neurons ([A–B] NeuN+ve and [C–D] PGP9.5). [E] DRG neuron siz
neuronal soma area Representative image of co-staining with [F] NeuN and
(scale bar = 100 mm).
Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mtin = 67.41 ± 4.83), Fig. 5C, D; PGP9.5; NS Unpaired
T test; (Vehicle = 60.59 ± 7.57 vs Cisplatin = 63.72 ±
8.01)), as well as no diﬀerence in size proﬁles of the
DRG neurons (Fig. 5E PGP9.5+ve; NS Two-way
ANOVA with post hoc Bonferroni; NeuN size proﬁle NS
Two-way ANOVA with post hoc Bonferroni, data not
shown) between experimental groups at P45.
Representative images of NeuN and PGP9.5 co-
localization in DRG neurons (Fig. 5F) and no primary
controls (Fig. 5G; cells positive for DAPI).
At P45 the total number of sensory DRG neuronal
subsets was calculated (Fig. 6A; co-labeled with NeuN)
with the total number of (Fig. 6B) CGRP and (Fig. 6C)
IB4-positive neurons determined. Representative merge
image of NeuN, CGRP and IB4-positive sensory DRG
neurons (Fig. 6D). There were no signiﬁcant changes in
the total number of CGRP+ve (Fig. 6E; NS Unpaired T
test; (Vehicle = 20.83 ± 0.83 vs Cisplatin = 19.67 +
1.04%)) and IB4+ve (Fig. 6F; NS Unpaired T test;
(Vehicle = 28.27 + 2.34 vs Cisplatin = 30.35 ± 1.15))
in either vehicle or the cisplatin-treated group.
Furthermore, DRG sensory neurons (PGP9.5+veory neurons were counted from both experimental groups (vehicle and
and PGP9.5. There was no diﬀerence in the total number of L4 DRG
e proﬁle demonstrating no change in neuron number per designated
PGP9.5 and of [G] no primary controls (vehicle = 5, cisplatin n= 5)
aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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416
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420
421
Fig. 6. The eﬀect of cisplatin treatment on DRG neuron subclass expression in adults. Sub-classiﬁcations of L4 DRG sensory neurons were
investigated in P45 animals in both vehicle and cisplatin groups. Total numbers of sensory DRG neurons were determined with [A] NeuN. Small
diameter sensory DRG neurons were labeled with [B] CGRP and [C] IB4. [D] Merged representation of NeuN, CGRP and IB4. There were no
diﬀerences between experimental groups (age-matched vehicle and cisplatin) in the total number of neurons expressing [E] CGRP or [F] IB4. Total
numbers of sensory DRG neurons were determined with [G] PGP9.5 when sensory DRG neurons were labeled for the myelinated sensory neuronal
marker [H] NF200 and small diameter sensory neuronal marker [I] TrkA. [J] Representative image of colocalized TrkA or NF200 with PGP9.5. There
were no diﬀerences between experimental groups (age-matched vehicle and cisplatin) in the total number of sensory neurons expressing [K]
NF200. However, there was an increase in the percentage of DRG neurons expressing [L] TrkA in the cisplatin group (*P< 0.05 Unpaired T test;
vehicle = 5, cisplatin n= 5) (scale bar = 100 mm).
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4 December 2017co-labeled Fig. 6G) labeled for (Fig. 6H) NF200+ve or
(Fig. 6I) TrkA (Fig. 6J; representative merge image of
PGP9.5, NF200 and TrkA-positive sensory DRG
neurons) demonstrated there (Fig. 6K; NS Unpaired422
423
424
425
426
427
428
Table 1. The eﬀect of cisplatin treatment on DRG neuron subclass
expression in adults. Total number of sensory DRG neurons express-
ing CGRP, IB4, NF200 or TrkA were determined in experimental
groups vehicle and cisplatin treat at P45 of age. (*P< 0.05 Unpaired T
test; vehicle = 5, cisplatin n= 5)
Vehicle Cisplatin
% Total Sensory Neuron
Number (Mean ± SEM)
% Total Sensory Neuron
Number (Mean ± SEM)
CGRP 30.88 ± 1.24 30.71 ± 1.63
IB4 41.88 ± 3.46 47.39 ± 1.79
NF200 41.05 ± 2.59 41.12 ± 3.49
TrkA 37.20 ± 2.09 49.59 ± 3.67*
Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the MT test; Vehicle = 27.70 + 1.74 vs Cisplatin = 26.70 ±
2.23) was no diﬀerence between the cisplatin-treated
group and the vehicle-treated group at P45 for total
number of NF200-positive neurons. However, there was
a signiﬁcant increase in the number of TrkA+ve DRG
neurons in the cisplatin group vs the vehicle group
(Fig. 6L; *P< 0.05 Unpaired T test; (Vehicle = 25.10
± 1.41 vs Cisplatin = 31.76 ± 2.35) at P45.
Percentage change in the sensory DRG neuron subsets
are represented as a proportion of total sensory DRG
neuron number (Table 1).429
430
431
432
433
434Early-life chemotherapy Results in immediate
alterations in sensory neuron termination within the
spinal dorsal horn
As well as innervating the skin, DRG neurons have a
reciprocal termination with the spinal cord DH. The
termination pattern of sensory neuron ﬁbers within theaturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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Fig. 7. Sensory nerve terminal innervation into dorsal horn is altered following cisplatin exposure.
In cisplatin postnatal day 16 (P16) animals there was increased immunoreactivity in the superﬁcial
dorsal horn of [A-B] CGRP (**p< 0.001 Two-way ANOVA) and [C–D] IB4 (
**p< 0.001 Two-way
ANOVA) compared to vehicle-treated age-matched rats. [E–F] TrkA distribution in the dorsal horn
was unaltered between vehicle and cisplatin treatment groups. A merged representation of CGRP,
IB4 and TrkA is presented for [G] vehicle and cisplatin (vehicle = 4, cisplatin n= 4; scale
bar = 100 mm).
Fig. 8. Cisplatin induced reorganization of sensory nerve ﬁber innervation into the dorsal horn. In
P16 cisplatin-treated animals [A-B] vGLUT2 sensory neuron innervation into the dorsal horn of the
spinal cord was increased versus age-matched vehicle-treated rats (*p< 0.05; Two-way ANOVA)
Additionally, there was no change in [C–D] NF200 immunoreactivity between the age-matched
vehicle and cisplatin-treated P16 rats (vehicle = 4, cisplatin n= 4; scale bar = 100 mm).
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4 December 2017DH was investigated following the end of cisplatin
treatment (P16) with signiﬁcant diﬀerences being
observed between the groups. Primary sensory nerve
aﬀerent terminals in the spinal cord were identiﬁed
through immunoreactivity for CGRP, IB4, and TrkA.Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Maturation of Pain Processing. NeuroThere was an increase in CGRP
(Fig. A-7B; (Vehicle = 39.64 ± 0.53
AUC vs Cisplatin = 52.02 ± 0.74AU
C) **P< 0.01 Two-way ANOVA) and
IB4 (7C-D; (Vehicle = 13.08 ± 0.14
AUC vs Cisplatin = 17.22 ± 0.26AU
C) **P< 0.01 Two-way ANOVA)
immunoreactivity in the dorsal horn
of cisplatin animals versus
age-matched vehicle controls.
Whereas there was no change for
TrkA (Fig. 7E, F; (Vehicle = 112.1
± 1.42AUC vs Cisplatin = 121.00
± 1.07AUC)). Demonstration of
colocalization and dorsal horn
laminae of CGRP, IB4 and TrkA in
vehicle and cisplatin-treated animals
(Fig. 7G). Additionally, vGLUT2
(Fig. 8A, B), which designates small
diameter sensory neurons,
demonstrated an increase in
vGLUT2 immunoreactivity in the P16
cisplatin-treated animals (Fig. 8B;
(Vehicle = 42.27 ± 0.36AUC vs Cis
platin = 61.32 ± 0.36AUC) *P<
0.05 Two-way ANOVA).
Furthermore, NF200 (Fig. 8C, D) for
myelinated primary sensory nerve
aﬀerents, there was no change in
NF200 (Fig. 8B; (Vehicle = 35.65 ±
0.65AUC vs Cisplatin = 43.04 ± 0.7
9AUC)) in the dorsal horn of
cisplatin-treated animals versus
vehicle controls.
At P45 sensory nerve aﬀerent
terminals in the spinal cord were
identiﬁed through immunoreactivity
for (Fig. 9A) CGRP, (Fig. 9B) IB4,
and (Fig. 9C) TrkA. CGRP sensory
inputs to the DH (Fig. 9E;
(Vehicle = 42.9 ± 2.61AUC vs Cis
platin = 43.65 ± 3.08AUC) NS Two-
way ANOVA) was unchanged, with
similar intensity and depth of
innervation into the dorsal horn
between vehicle and cisplatin
groups. There was a small increase
in IB4 staining in the dorsal horn of
the spinal cord of cisplatin-treated
animals (Fig. 9F; (Vehicle = 23.63
± 0.90AUC vs Cisplatin = 27.87 ±
1.25AUC) *P< 0.05 Two-way
ANOVA). There was an increase in
TrkA immunoreactivity intensity and
depth of innervation in the cisplatin
group versus age-matched vehicle
controls (Fig. 9G; (Vehicle = 53.23± 2.83AUC vs Cisplatin = 93.54 ± 4.46AUC) **P<
0.01 Two-way ANOVA; representative
colocalization/dorsal laminae images Fig. 9G).
Furthermore, vGLUT2 (Fig. 10A-B; (Vehicle = 19.75 ±science (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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Fig. 9. Cisplatin treatment early in life leads to increased innervation of sensory aﬀerent terminals in the superﬁcial dorsal horn in adult rats.
Sensory nerve ﬁber terminals within the dorsal horn of 45 day old rats (treated with either vehicle or cisplatin) were deﬁned using [A] CGRP, [B] IB4
and [C] TrkA immunoreactivity. [D] Representative overlay images of the dorsal horn displaying CGRP, IB4 and TrkA nerve terminals in the vehicle
and cisplatin groups. There was no change in the depth by which [E] CGRP+ve nerve ﬁber terminated in the dorsal and there was no change in the
intensity within the dorsal horn in either experimental group (vehicle or cisplatin). [F] However, there was an increase in IB4 intensity (
*P< 0.05
Two-way ANOVA; vehicle = 5, cisplatin n= 5) within the dorsal horn of cisplatin-treated animals compared to vehicle. [G] There was also an
increase in intensity as well as depth of the TrkA+ve sensory nerve innervation in the dorsal horn of cisplatin-treated animals versus control.
(**P< 0.01 Two-way ANOVA; vehicle = 5, cisplatin n= 5). Representative merge image of CGRP, IB4 and TrkA and NF200 (scale bar = 100
mm).
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4 December 20170.17AUC vs Cisplatin = 44.01 ± 0.29AUC) **P< 0.01
Two-way ANOVA) as well as NF200 (Fig. 10C-D; (Vehi
cle = 18.04 ± 0.43AUC vs Cisplatin = 36.2 ± 0.92AU
C) *P< 0.05 Two-way ANOVA; representative merge
image Fig. 10E) input into the spinal cord was also
increased in the cisplatin-treated animals.
Cisplatin-treated animals at P16 did not show any
change in the number of NeuN-positive neuronal cell
bodies (Fig. 11A–C; NS; Unpaired T test; (Vehicle = 19.
18 ± 4.49 vs Cisplatin = 18.58 ± 3.98)) or GFAP
expressing astrocytes (Fig. 11D-F; NS; Unpaired T test;
(Vehicle = 7.08 ± 0.19 vs Cisplatin = 6.79 ± 0.32)) in
the dorsal horn when compared to age-matched vehicle
controls. At P45 cisplatin-treated animals did not show
any change in neuron number (NeuN) (Fig. 11G–I; NS;
Unpaired T test; (Vehicle = 16.8 ± 3.60 vs Cisplatin =
17.72 ± 3.46)) or astrocyte number (GFAP) (Fig. 11 J-
K; NS; Unpaired T test; (Vehicle = 2.88 ± 0.38 vs Cispla
tin = 3.18 ± 0.23)) at P45 across the entire spinal cordPlease cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the MDH. However, in lamina V of the DH there was a
signiﬁcant increase in astrocyte expression of GFAP in
cisplatin-treated adult rats (Fig. 11L; P< 0.01; Unpaired
T test).DISCUSSION
Chemotherapy is crucial for the treatment of cancer.
Improvements in basic research, diagnosis and the
advancement of anti-cancer strategies, have led to a
considerable improvement in cancer survival rates.
However, as a consequence of this patients and families
are commonly expected to deal with the adverse long-
lasting side eﬀects of treatment. Platinum-based drugs
are widely used to treat cancers and are commonly
associated with sensory neuropathy in adult patients.
Unfortunately, many childhood cancers are also treated
with such cytotoxic agents and they can have a
devastating impact upon the development of the patient.aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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Fig. 10. Cisplatin treatment early in life leads to increased innervation of sensory aﬀerent terminals in the superﬁcial and deep dorsal horn in adult
rats. [A] vGLUT2+ve sensory aﬀerent nerve terminals were found to terminate in the superﬁcial lamina (lamina I) in the vehicle group. However, [B]
there is a wide spread increase in the cisplatin group when compared to vehicle animals (**P< 0.01 Two-way ANOVA; vehicle = 5, cisplatin n=
5). [C] NF200 immunoreactivity demonstrates [D] an increase in myelinated structures within the dorsal horn of the spinal cord of cisplatin animals
versus the vehicle group (*P< 0.05 Two-way ANOVA; vehicle = 5, cisplatin n= 5). [E] Representative merge image of VGlut2 and NF200 (scale
bar = 100 mm).
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4 December 2017Although side-eﬀects of treatment are well recognized
(e.g. diﬃculties in learning and social interactions,
hearing and vision (Grewal et al., 2010; Clanton et al.,
2011), there has been minimal investigation into the
impact that early-life exposure to chemotherapy has upon
somatosensory development. Here we have investigated
the eﬀects of cisplatin treatment in young rodents and
upon the maturing nociceptive systems in the periphery
nervous system and dorsal horn of the spinal cord. Our
data show that early-life cisplatin treatment leads to a
delayed but prolonged pain hypersensitivity that is associ-
ated with a remodeling of the sensory nervous systems.567
568
569
570
571
572
573
574Cisplatin induced pain in adult childhood cancer
survivors
CIPN is one of the most common side-eﬀects and can be
a treatment terminating ailment. The DRG sensory
neurons are damaged by chemotherapy and a number
of rodent studies have investigated this in the adultPlease cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mwhereby mitochondrial dysfunction (Flatters and
Bennett, 2006; Jin et al., 2008) and/or hindered growth
factor support (Vencappa et al., 2015) are primary causes
of CIPN. However, despite the extensive research in
humans and rodents to investigate adult CIPN, to date
minimal research has been undertaken to investigate
childhood cancers and the consequent treatment eﬀects
on quality of life. Childhood cancers are rare, however
the 10-year survival rate for children surviving cancer is
75–80%. Therefore it is a clinical and moral necessity that
the quality of life for these cancer survivors needs to be
considered, especially as these pediatric patients are still
undergoing signiﬁcant bodily development. It is reported
that 50% of 10,397 adult childhood cancer survivors
highlight pain as a side-eﬀect of treatment (Lu et al.,
2011), and many are dependent on prescribed analgesia
medication (Lu et al., 2011). Childhood cancer patients
who have undergone chemotherapy (e.g. vincristine, cis-
platin, methotrexate) treatment display signs of sensory
neuropathic pain later in life, typically associated with ado-aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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Fig. 11. Cisplatin treatment early in life does not alter sensory neuron number and increases astrocytic activation in the dorsal horn. In P16
age-matched rats that were treated with either cisplatin or vehicle demonstrate no change in [A–B] total neuron number (NeuN) in the dorsal horn.
When comparing lamina there were also no diﬀerences in [C] total neuron number per laminae. [D–E] Astrocyte (GFAP) number was also
unchanged in the dorsal horn in P16age-matched rats treated with either cisplatin or vehicle. There were no diﬀerences in [F] total astrocyte number
across lamina I, II and V. In adult (P45) rats treated with cisplatin early in life there were no diﬀerences in [G–I] total neuron number (NeuN) across
dorsal horn laminae when compared to vehicle-treated age-matched controls. [J–K] There was no change in total astrocyte (GFAP) number,
however, there was an increase in lamina V ofGFAP-positive astrocytes (*P< 0.05 Unpaired t test; vehicle = 5, cisplatin n= 5) (scale bar = 100
mm).
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4 December 2017lescence (Lu et al., 2011; Ness et al., 2013; Khan et al.,
2014). Patients who are diagnosed with cancer in early
life (<10 years old) and are then assessed later in life,
present symptoms of CIPN such as hypersensitivity to
mechanical stimulation in the hands and arms (Gilchrist
and Tanner, 2013; Gilchrist et al., 2014), as well as hall-
marks of sensory neurodegeneration (Lu et al., 2011;
Khan et al., 2014). These symptoms occur many years
after diagnosis and the end of treatment (>7 yrs)
Phillips et al., 2015; Khan et al., 2014. The data presented
in this study complement these human studies, whereby
early-life treatment with cisplatin leads to the development
of neuropathic pain, but this pain does not present until
later in life. This delay in the manifestation of neuropathic
pain until adulthood when the injury was in early life has
been seen with other animal models (McKelvey et al.,
2015) and recently presented following early-life exposure
to vincristine (Schappacher et al., 2017). It must be notedPlease cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mthat acute toxicity and hypersensitivity from chemother-
apy exposure has been demonstrated (Joseph and
Levine, 2009). In this study acute pain (within hours of
drug administration) were not investigated and could be
missed. However, heat hypersensitivity develops at a
timepoint much later following ﬁnal cisplatin injections
despite regular nociceptive testing. This highlights our pri-
mary focus of this study on understanding alterations to
the sensory nervous system in adulthood following cis-
platin treatment. This further explains our rationale for
our chosen methodology for the development of this child-
hood model of CIPN. Cisplatin administration in humans
is typically multiple cycles of treatment (Zsiros et al.,
2013) and adult rodent models have been developed to
explore CIPN in this setting (Mao-Ying et al., 2014). How-
ever, these studies aimed to determine how cisplatin
impacts upon sensory neuron development therefore
requiring a focussed delivery timeline to allow identiﬁca-aturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
G. J. Hathway et al. / Neuroscience xxx (2017) xxx–xxx 13
NSC 18147 No. of Pages 16
4 December 2017tion of any nociceptive changes. These data provide the
ﬁrst insight into how cancer treatment can impact upon
the developing sensory nervous system and conse-
quently chronic pain in adult childhood cancer survivors.
Cisplatin exposure is associated with long lasting
pain
CIPN is long-lasting in adults with pain persisting for many
months or years post termination of treatment (Flatters
and Bennett, 2006; Paice, 2009; Paice, 2011). Sensory
neuronal apoptosis is thought to be restricted to the
peripheral nervous system (Jacobs et al., 2010), with neu-
ropathy symptoms typically displayed in the extremities
e.g. hands or feet. Targeting of which, can alleviate plat-
inum-based chemotherapy-induced sensory neuropathy
(Joseph and Levine, 2009). Despite this obvious impact
upon the sensory nervous system particularly in adults
and known implications of chemotherapy toxicity to chil-
dren, minimal information is available on chemotherapy-
induced pain in adult childhood cancer survivors. There
are increased neurological symptoms in adult childhood
cancer patients such as auditory complications (Grewal
et al., 2010). Here we present evidence that young ani-
mals treated with cisplatin develop a delayed but long
lasting pain. The sensory nervous system develops and
matures over the ﬁrst weeks of life; C ﬁber integration into
the spinal dorsal horn and both intrinsic and descending
inhibitory tone within the dorsal horn is established
(Jennings and Fitzgerald, 1998; Koch et al., 2012), vastly
improving motor and sensory acuity (Fitzgerald, 2005). In
association neuropathic pain only becomes established 3
weeks postnatally if a traumatic nerve injury is introduced
during the initial 2 weeks of life (Vega-Avelaira et al.,
2012; McKelvey et al., 2015). Our data demonstrate that
cisplatin treatment administered during the second week
of life induces neuropathic pain that develops 22 days
post-natally. This is highly comparable to studies in pedia-
tric patients whereby pain is uncommon in young children
(Walco et al., 2010), however neurological complications
and pain are increasingly common in patients with
increasing age (Phillips et al., 2015).
Understanding how such chemotherapy treatments
impact upon the developing sensory nervous system
allows us to design and provide suitable analgesic relief
and treatment management to these patients. It is
known that if you introduce a noxious insult e.g.
traumatic nerve or incisional injury to young individuals
that long-lasting pain does not necessarily become
apparent until later in life. This has been displayed
recently in rats and mice where a spared nerve injury in
the ﬁrst post-natal week led to a delayed hyperalgesia
(McKelvey et al., 2015). In addition, this is comparable
to human studies where pain does not present until much
later in life (Fitzgerald, 2005; Vega-Avelaira et al., 2012;
Fitzgerald and McKelvey, 2016). Furthermore, in neonatal
animals there is a signiﬁcant loss of sensory neurons in
the initial post-natal weeks (Coggeshall et al., 1994) which
is exacerbated following nerve injury (Himes and Tessler,
1989). It has been reported that cisplatin and other plat-
inum-based drugs induce neuronal apoptosis (Gill and
Windebank, 1998). However, cisplatin treatment in post-Please cite this article in press as: Hathway GJ et al. Cancer Chemotherapy in Early Life Signiﬁcantly Alters the Mnatal week 2 does not lead to alterations in DRG neuronal
number or sub-classiﬁcations in the immature (P16) tis-
sue but demonstrates increases in neuronal stress pre-
sented by increases in cleaved caspase III when
compared to the vehicle group in the immature group.
Interestingly the tissue extracted from adult (P45) rats
treated with cisplatin also do not display any diﬀerence
in DRG number or alterations in DRG neuron soma size
compared to vehicle control animals therefore cisplatin-
induced sensory neuropathy is not associated with neu-
ronal apoptosis in this instance. However, following a
traumatic nerve injury, sensory DRG neurons have the
capability to regenerate, hyperinnervating peripheral and
central targets (Himes and Tessler, 1989; Shortland and
Fitzgerald, 1994). There can be expansive remodeling
of peripheral nerve innervation patterns in the skin
(Reynolds and Fitzgerald, 1995) as well as into the dorsal
horn of the spinal cord (Shortland and Fitzgerald, 1994);
which is typiﬁed by a spike in nerve growth factor expres-
sion in neonatal and adult rodents (Lewin and Mendell,
1994; Constantinou et al., 1994). Cisplatin treatment in
the second post-natal week led to striking a hyperinnerva-
tion in adults, with an increased IENF into the plantar skin
of CGRP+ve and PGP9.5+ve nerve ﬁbers. This is
accompanied by alterations in the innervation pattern of
the sensory aﬀerent central terminals with elevated levels
and/or alterations in depth of lamina innervation displayed
by C ﬁbers and A ﬁbers. As mentioned sensory axonal
and nerve ﬁber processes do have the ability to recover
following chemotherapy treatment (Flatters and Bennett,
2006), however such chemotherapy treatments poten-
tially initiates aberrant growth of sensory nerve ﬁbers
due to the impact on developing tissues as highlighted
whereby NGF is administered in neonatal peripheral tis-
sues (Lewin and Mendell, 1994; Constantinou et al.,
1994). This is in contrast to earlier timepoints where IENF
innervation is reduced following cisplatin treatment. It is
known that the sensory nerve can regenerate following
an insult (Ma et al., 2011) and that treatment or disease
induces uncontrolled aberrant sensory nerve ﬁber growth,
to which is associated with chronic pain development
such as in rodent models of arthritis (Ghilardi et al.,
2012) and cancer pain (Bloom et al., 2011). We postulate
here that despite initial suppression of the regenerative
capacity (decrease in ATF3 expression (Vencappa
et al., 2015) following cisplatin exposure, endogenous
regenerative mechanisms are induced driving this aber-
rant growth. Further understanding of these mechanisms
is needed to allow us to potentially identify key mecha-
nisms associated with chronic pain development.
Changes in C ﬁber innervation patterns peripherally
and centrally we believe could be attributable to the
delayed but long-lasting pain induced by cisplatin.
Furthermore, the onset of mechanical and heat
hyperalgesia can be associated with the onset of C ﬁber
sensitization (Djouhri et al., 2001; Djouhri et al., 2006;
Hulse et al., 2010; Hulse, 2016). This can be prevented
through the inhibition of the NGF-TrkA axis (Djouhri
et al., 2001). It is plausible that cisplatin-induced survivor-
ship pain is mediated by TrkA-dependent mechanisms,
which is widely acknowledged as a key component ofaturation of Pain Processing. Neuroscience (2017), https://doi.org/10.1016/j.neuroscience.2017.11.032
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4 December 2017sensory neuron trophic support and chronic pain develop-
ment (Bloom et al., 2011; Ghilardi et al., 2012). Induction
of NGF-TrkA signaling is highly plausible as the percent-
age of sensory DRG neurons expressing TrkA (tropomy-
sin receptor kinase A) as well as dorsal horn innervation
of TrkA-positive sensory aﬀerent terminals were upregu-
lated in the cisplatin adult (P45) group versus vehicle
age-matched controls. Aberrant branching of sensory
nociceptors has been widely associated with the develop-
ment of hyperalgesia and peripheral sensory nerve sen-
sitization typically associated with disease such as
arthritis (Jimenez-Andrade and Mantyh, 2012) and bone
cancer (Jimenez-Andrade et al., 2010; Bloom et al.,
2011). With regards to A ﬁber function; A ﬁber sen-
sitization has been associated with onset of chronic pain
(Tsantoulas et al., 2012) and that A ﬁber sensitization
occurs comparably in inﬂammatory arthritis in both hairy
and glabrous skin (Drake et al., 2014). However, our con-
clusions as regards delayed onset of chronic pain need to
also consider that descending control can impact upon
nociceptive processing with regards to A ﬁber inputs, to
the instance that A ﬁber induced chronic pain can be
blocked via activation of inhibitory descending modulation
(Drake et al., 2014). This is in addition to decreased A
ﬁber innervation into the hairy surface of the hindpaw
which would lead to reduced sensory dexterity (Boada
et al., 2010). Therefore delayed mechanical allodynia in
this instance could be due to inhibitory descending control
or alternatively due to lack of sensitization on the hairy
side of the hindpaw.
CIPN is a common complaint of adults receiving
chemotherapy, especially cisplatin, in addition to the
inability to sleep, low mood and diﬃculty performing
everyday tasks. It is important in clinical practice to
understand the long-term eﬀects of chemotherapy on
children and the developing nervous system. Childhood
cancer survivors appear to have a delayed onset of
neuropathic pain compared to adults for whom there is
an immediate onset of allodynia and hyperalgesia.
Plasticity in the immature nervous system and impact of
cisplatin treatment leads to the normal development of
nociceptive pathways being disrupted. A change in pain
processing due to chemotherapy treatment, manifesting
as hypersensitivity, could impact patient quality of life.
Few studies, however, have documented the late eﬀects
of chemotherapeutic agents in pediatric patients or the
future impact of CIPN. Hence, the hyperalgesia
observed here holds clinical importance with many
patients experiencing late eﬀects of their treatment.
Clinically, an intervention which prevents abnormal
maturation yet provides symptom relief may be viable in
the future.848
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